Kalaris Therapeutics, Inc. (KLRS)
2.26
-0.10
(-4.24%)
USD |
NASDAQ |
Oct 12, 16:00
2.23
-0.03
(-1.33%)
After-Hours: 20:00
Kalaris Therapeutics Enterprise Value : -38.34M for Oct. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 12, 2026 | -38.34M |
| October 09, 2026 | -35.96M |
| October 08, 2026 | -32.63M |
| October 07, 2026 | -31.20M |
| October 06, 2026 | -28.82M |
| October 05, 2026 | -24.77M |
| October 02, 2026 | -27.86M |
| October 01, 2026 | -24.29M |
| September 30, 2026 | -23.34M |
| September 29, 2026 | -23.10M |
| September 28, 2026 | -24.41M |
| September 25, 2026 | -22.63M |
| September 24, 2026 | -19.06M |
| September 23, 2026 | -17.87M |
| September 22, 2026 | -15.01M |
| September 21, 2026 | -14.89M |
| September 18, 2026 | -15.96M |
| September 17, 2026 | -16.91M |
| September 16, 2026 | -16.44M |
| September 15, 2026 | -15.96M |
| September 14, 2026 | -13.58M |
| September 11, 2026 | -11.68M |
| September 10, 2026 | -13.58M |
| September 09, 2026 | -9.535M |
| September 08, 2026 | -5.726M |
| Date | Value |
|---|---|
| September 04, 2026 | 0.7015M |
| September 03, 2026 | 1.654M |
| September 02, 2026 | 0.7015M |
| September 01, 2026 | 1.178M |
| August 31, 2026 | 4.034M |
| August 28, 2026 | 3.796M |
| August 27, 2026 | 5.462M |
| August 26, 2026 | 4.986M |
| August 25, 2026 | 7.843M |
| August 24, 2026 | 5.462M |
| August 21, 2026 | 6.653M |
| August 20, 2026 | 5.939M |
| August 19, 2026 | 7.129M |
| August 18, 2026 | 3.796M |
| August 17, 2026 | 2.130M |
| August 14, 2026 | 4.986M |
| August 13, 2026 | 0.2254M |
| August 12, 2026 | 1.654M |
| August 11, 2026 | 2.368M |
| August 10, 2026 | 1.654M |
| August 07, 2026 | 4.748M |
| August 06, 2026 | 7.605M |
| August 05, 2026 | 7.605M |
| August 04, 2026 | 10.70M |
| August 03, 2026 | 4.272M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Replimune Group, Inc. | 1.014B |
| Arrowhead Pharmaceuticals, Inc. | 8.346B |
| Oncolytics Biotech, Inc. | 55.32M |
| Sangamo Therapeutics, Inc. | 53.89M |
| Sarepta Therapeutics, Inc. | 2.099B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.52M |
| Total Expenses (Quarterly) | 11.52M |
| EPS Diluted (Quarterly) | -0.4839 |
| Earnings Yield | -89.12% |
| Normalized Earnings Yield | -89.12 |